Founder and CEO, Europacifica Consulting

Naomi Fink

Founder and CEO

Europacifica Consulting

Thematic (Sector/Industry)

<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/015/017/original/IRF_NewsShocks.png?1476919557" class="editor-image img-responsive" data-smartkarma-image-id="15017"></figure><div class="content-caption">"News Shocks" to the Japanese Economy (Source: Europacifica)</div><h2>Room for small hope amid bleak Japanese policy reform record</h2><p>Until now, our analysis of Japanese structural reform, centred upon raising Japanese productivity, has revealed few tendencies that might give us hope of an imminent and conclusive end to Japan's deflationary "lost decades" dynamic.  In <a href="https://www.smartkarma.com/insights/structural-reform-i-the-japanese-financial-sector" target="_blank" data-smartkarma-citation="insights:6375">Structural Reform I: The Japanese Financial Sector</a> we examined some of the structural characteristics within the financial sector that were…</p>

"News Shocks" to the Japanese Economy (Source: Europacifica)Room for small hope amid bleak Japanese policy reform recordUntil now, our analysis of Japanese structural reform, centred upon raising Japanese productivity, has revealed few tendencies that might give us hope of an imminent and conclusive end to Japan's deflationary "lost decades" dynamic.  In Structural Reform I: The Japanese Financial Sector we examined some of the structural characteristics within the financial sector that were…

Structural Reform III: Evidence of Bad Luck over Poor Policy

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

<p>Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate and 67% clinical response rate). The company will also present data from an on-going phase 2 study of ozanimod, S1P1 modulator at upcoming scientific conferences, including the American College of Gastroenterology annual meeting. Our sentiment: Bullish</p><p>Tetraphase Pharmaceuticals (NASDAQ: TTPH) started a phase 3 trial of its antibiotic candidate…</p>

Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate and 67% clinical response rate). The company will also present data from an on-going phase 2 study of ozanimod, S1P1 modulator at upcoming scientific conferences, including the American College of Gastroenterology annual meeting. Our sentiment: BullishTetraphase Pharmaceuticals (NASDAQ: TTPH) started a phase 3 trial of its antibiotic candidate…

Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

<p>The Topix pharmaceutical index (TPPHRM) fell to 2,355 just after the lunch break in Tokyo on Friday 19th August, before recovering to 2,377, with the market's afternoon rally. That though was still a 52-week daily-close low. In August, alone, the sector is down 10%. This can in part be explained by bad news - <a href="https://www.smartkarma.com/entities/8979" target="_blank" data-smartkarma-citation="entities:8979:1">Ono Pharmaceutical</a>'s shares have been hit by negative news over Opdivo (see <a href="https://www.smartkarma.com/insights/opdivo-fails-nsclc-test" target="_blank" data-smartkarma-citation="insights:5134">Opdivo Fails NSCLC Test)</a> - however, <a href="https://www.smartkarma.com/entities/4489" target="_blank" data-smartkarma-citation="entities:4489:1">Chugai Pharmaceutical</a> has fallen from ¥3,865 to ¥3,205 over the same time and…</p>

The Topix pharmaceutical index (TPPHRM) fell to 2,355 just after the lunch break in Tokyo on Friday 19th August, before recovering to 2,377, with the market's afternoon rally. That though was still a 52-week daily-close low. In August, alone, the sector is down 10%. This can in part be explained by bad news - Ono Pharmaceutical's shares have been hit by negative news over Opdivo (see Opdivo Fails NSCLC Test) - however, Chugai Pharmaceutical has fallen from ¥3,865 to ¥3,205 over the same time and…

Bespoke Research on China and neighbouring regions, Bixmoor

Bixmoor

Bespoke Research on China and neighbouring regions

Bixmoor specialises in providing bespoke research to business, governments and the financial community on China and neighbouring regions. We seek to build long-term relationships with our clients, based on our expertise, our reliability and our determination to find the right solution.

<p>A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest height gain of any developed country, whereas Koreans have grown by an average of six inches over the last 100 years. </p>

A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest height gain of any developed country, whereas Koreans have grown by an average of six inches over the last 100 years. 

<p>While it is not a given that a switch from a high growth, high interest rate environment to a low growth, low interest rate environment is a good one for equities in general, it should be good for defensive stocks, because these are the most bond-like of equities and the switch almost defines a fixed income bull market. Japan may not have been particularly high growth or high interest rate in 2000, but it was certainly higher growth and higher interest rate than today, and it is no surprise that defensive sectors like foods (+210% relative to Topix since 1999) and pharmaceuticals (+160%) have done very well over this time.<br><br>The question, now, is whether this is set to continue, or whether we might have hit a turning point.</p>

While it is not a given that a switch from a high growth, high interest rate environment to a low growth, low interest rate environment is a good one for equities in general, it should be good for defensive stocks, because these are the most bond-like of equities and the switch almost defines a fixed income bull market. Japan may not have been particularly high growth or high interest rate in 2000, but it was certainly higher growth and higher interest rate than today, and it is no surprise that defensive sectors like foods (+210% relative to Topix since 1999) and pharmaceuticals (+160%) have done very well over this time.  The question, now, is whether this is set to continue, or whether we might have hit a turning point.

Japan

Mitsubishi Tanabe Pharma Corporation produces pharmaceutical products. The Company produces drugs for cardiac arrest, hypertension,circulatory disease, and ulcer.  Mitsubishi Tanabe Pharma also makes health care products including nutritious supplements for elderly, food additives, pesticide, cosmetics, and medical products for veterinary use.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mitsubishi Tanabe Pharma (4508 JP)

Structural Reform III: Evidence of Bad Luck over Poor Policy

Room for small hope amid bleak Japanese policy reform recordUntil now, our analysis of Japanese structural reform, centred upon raising Japanese...

Naomi Fink

Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17

Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate...

Dr. Bhavneesh Sharma, MD, MBA

Japan Pharma Hits 52 Week Low

The Topix pharmaceutical index (TPPHRM) fell to 2,355 just after the lunch break in Tokyo on Friday 19th August, before recovering to 2,377, with...

Pelham Smithers Associates

A 'heads Up' on Changing World Heights

A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest...

Bixmoor

Death Rattle for Defensives?

While it is not a given that a switch from a high growth, high interest rate environment to a low growth, low interest rate environment is a good...

Pelham Smithers Associates

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)